Antithrombin III concentrate in the acute phase of thermal injury

Background: Thermal injury disrupts homeostasis by inducing subclinical dis seminated intravascular coagulation, fibrinolysis; and an acquired deficien cy of Antithrombin III (ATIII), a natural anticoagulant. As a result, therm ally injured patients have a high incidence of hypercoagulability and throm bosis. Objective: ATIII (Human) concentrate was given to a thermally injure d patient to evaluate safety, and dosage requirements in this setting. Desi gn: The patient was a 40 yr old male with a 68% total burn surface area, ri ght femoral comminuted fracture, and C5-C6 subluxation sustained in a vehic ular crash. He received nine infusions of AT III (H) concentrate (100-50 u/ kg) within the first four days of injury. Result: The ATIII plasma level in creased from 45% on admission (normal = 100 +/- 20%) to 120 +/- 25% in the next four days. During the 64 day hospitalization, there were 11 grafting p rocedures with an estimated blood loss (EEL)/procedure: 1140 cc; and EBL/gr afted surface area ratio: 0.6 cc/cm(2). The average time to healing of the meshed autograft was 6.4 days. Conclusion: ATIII (H) concentrate can be saf ely utilized in the acute phase of thermal injury: no excessive bleeding or prolongation of wound healing was documented. (C) 2000 Elsevier Science Lt d and ISEI. All rights reserved.